Furthermore, according to preclinical investigations, CAR T-cell therapy targeting FAP could be combined with cancer vaccines or immune checkpoint blockers such as anti-PD-1 and anti-CTLA4 and results in the blockade of some of the immunosuppressive factors such as DGKξ and TGF-β [90]. This evidence concerns the gene FAP and cancer.